Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

INTRODUCTION: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, is approved in the USA to reduce risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus (T2DM) and established CV disease, based on EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifsnider, Odette S, Kansal, Anuraag R, Gandhi, Pranav K, Cragin, Lael, Brand, Sarah B, Pfarr, Egon, Fahrbach, Kyle, Ustyugova, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098979/
https://www.ncbi.nlm.nih.gov/pubmed/33941549
http://dx.doi.org/10.1136/bmjdrc-2020-001313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098979/
https://www.ncbi.nlm.nih.gov/pubmed/33941549
http://dx.doi.org/10.1136/bmjdrc-2020-001313

Ejemplares similares